Blinatumomab superior to chemotherapy for refractory ALLMarch 1, 2017Leukemia, Myelodysplasia, Transplantation
Older AML patients benefit from frailty assessment and interventionsFebruary 25, 2017Leukemia, Myelodysplasia, TransplantationPatient & Survivor Care
Ublituximab was safe, highly active in rituximab-pretreated B-cell NHL, CLLFebruary 21, 2017Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
In CLL, specific mutation is key to ibrutinib resistanceFebruary 13, 2017Leukemia, Myelodysplasia, Transplantation
In active CLL with deletion 17p, consider trial enrollmentFebruary 9, 2017Leukemia, Myelodysplasia, Transplantation
AML leads percent gains in 5-year survival among leukemiasJanuary 30, 2017Leukemia, Myelodysplasia, Transplantation
Ruxolitinib beats best available care for hematocrit control in polycythemiaJanuary 24, 2017Leukemia, Myelodysplasia, Transplantation
Clonal hematopoiesis increases risk for therapy-related cancersJanuary 21, 2017Patient & Survivor CareLeukemia, Myelodysplasia, Transplantation
Palliative care improves quality of life after HCTJanuary 19, 2017Patient & Survivor CareLeukemia, Myelodysplasia, Transplantation
Lenalidomide maintenance extended progression-free survival in high-risk CLLJanuary 17, 2017Leukemia, Myelodysplasia, Transplantation
Adding epoetin alfa to lenalidomide boosted myelodysplastic syndrome responsesJanuary 5, 2017Leukemia, Myelodysplasia, Transplantation
